复星国际2026年中期归母净利润同比大增160.3%至17.2亿元人民币，但收入持平、利润增长依赖低基数与资产处置

Fosun International Limited (0656.HK) reported interim results for the six months ended June 30, 2026, highlighting stable revenue, sharply higher profit and continued progress across its innovation, healthcare and global operations.
Total revenue reached RMB86.96 billion, compared with RMB87.28 billion in the prior-year period.
The profit attributable to owners of the parent surged 160.3% year over year to RMB1.72 billion from RMB661.2 million.
Industrial operation profit increased 17% to RMB3.69 billion from RMB3.15 billion, reflecting improved operational quality across the Group's core businesses.
Financial Performance
Overseas revenue increased 5.3% to RMB49.16 billion from RMB46.67 billion in the prior-year period, accounting for 56.5% of total revenue compared with 53.0% a year earlier and underscoring Fosun's continued focus on globalization.
The Group generated more than RMB12 billion in proceeds from divesting non-strategic and non-core assets during the first half.
Cash, bank balances and term deposits totaled RMB61.21 billion as of June 30, 2026, while the total debt-to-total capital ratio stood at 55.7%.
Fosun's core subsidiaries, including Fosun Pharma, Yuyuan, Fidelidade and its Tourism segment, generated combined revenue of RMB63.88 billion, representing 73.5% of the Group's total revenue, compared with RMB63.61 billion, or 73.0% of revenue, in the prior-year period.
Healthcare And Innovation Progress
Investment in technology innovation increased 16.7% year over year to RMB4.2 billion from RMB3.6 billion.
Fosun Pharma had 20 indications across seven innovative drugs approved for launch in domestic and overseas markets, compared with five indications across four innovative drugs approved in the first half of 2025.
Fosun Pharma generated operating revenue of RMB20.38 billion, while innovative drug revenue increased 13.84%, accounting for 33.35% of pharmaceutical business revenue.
Henlius reported revenue growth of 27.3% to RMB3.59 billion, while net profit increased 10.3% to RMB430.4 million.
HANSIZHUANG received approval for a perioperative gastric cancer indication in China, while multiple clinical studies continued for the PD-L1 ADC HLX43.
Clinical studies for HLX43 span Phase 1, Phase 2 and global Phase 2/3 trials across multiple solid tumor indications.
Phase 1 studies evaluated safety, tolerability, pharmacokinetics and dose escalation in patients with advanced or metastatic solid tumors.
Phase 2 studies are evaluating HLX43 as a monotherapy and in combination regimens, including with serplulimab, in indications such as non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma (ESCC).
The program has also advanced into global Phase 2/3 development, including the multi-country HLX43-NSCLC302 registration trial in squamous non-small cell lung cancer (sqNSCLC), supporting the potential expansion of HLX43 across solid tumor indications.
The company also expanded AI applications across drug discovery and development, with Fosun Pharma advancing more than 25 high-value AI projects and over 50 use cases.
Two AI-assisted and structurally generated molecules entered the preclinical candidate stage.
Global Operations And Outlook
Fosun continued expanding its global presence, with its healthcare, insurance, consumer, tourism and intelligent manufacturing businesses reporting progress across international markets.
Fosun Pharma's overseas revenue increased 16.45%, while Pramerica Fosun Life Insurance reported a 52.2% increase in gross written premiums and a 270% increase in net profit.
The Group's MSCI ESG rating was upgraded to AAA, the highest rating.
Looking ahead, Fosun said it will continue focusing on innovation, globalization and its core businesses, with the long-term goal of steadily restoring annual profit to the RMB10 billion level.
0656.HK has traded between HKD 3.42 and HKD 5.79 over the last year.
The stock is closed Thursday's trading at HKD 5.41 up 2.56%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.